Samsung Biologics Announces 'Main Track' at JPMHC for 8 Consecutive Years

Samsung Biologics announced on the 26th that it will participate in the '2024 JP Morgan Healthcare Conference (JPMHC),' the largest pharmaceutical and biotech investment conference in the United States.

At the 41st JP Morgan Healthcare Conference held last January, John Rim, CEO of Samsung Biologics, is delivering a main track presentation.
[Photo by Samsung Biologics]

The 42nd JPMHC, held from February 8 to 11 (local time) in San Francisco, California, is considered the largest event in the pharmaceutical and biotech investment industry. This year, it is expected that 600 pharmaceutical, biotech, and healthcare companies and over 8,000 corporate representatives and investors will gather in one place.

On the 9th at 3:45 PM, Samsung Biologics CEO John Rim will present under the theme "Leap Forward, Beyond the Reach of the Past," explaining the major achievements of 2023, the outlook for 2024, and the mid- to long-term vision. More detailed plans regarding the construction of an antibody-drug conjugate (ADC) manufacturing facility, targeted to begin production next year, are expected to be revealed.

Samsung Biologics' presentation this year marks its eighth consecutive official invitation from JP Morgan since 2017, taking place in the core presentation section called the 'Main Track.' The Main Track presentations are held in the largest venue of the event, the Grand Ballroom of the Westin St. Francis Hotel, and are the most highly regarded presentations assigned to major players.

Notably, the order of Main Track presentations is generally arranged according to industry-leading companies. While Samsung Biologics' presentation has traditionally been on the third day, this year it has been moved up to the second day for the first time. It is scheduled to present 16th overall, following Eli Lilly and AstraZeneca (AZ).

In addition, Samsung Biologics stated that during the event, it will hold meetings with investors and potential clients, focus on promoting its differentiated global contract development and manufacturing organization (CDMO) competitiveness, and work to expand partnerships.

This content was produced with the assistance of AI translation services.